The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs

Mario I. Vega Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California, USA; Unidad de Investigacion Medica en Inmunologia e Infectologia, Hospital de Infectologia, CMN “La Raza”, IMSS, Mexico

Melissa Martinez-Paniagua Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California, USA

Ali R. Jazirehi Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California, USA

Sara Huerta-Yepez Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California, USA; Unidad de Investigacion En Enfermedades Oncologicas, Hospital Infantil de Mexico, Federico Gomez, S.S.A., Mexico

Kazuo Umezawa Department of Applied Chemistry, Keio University, YokohamaJapan

Otoniel Martinez-Maza Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California, USA; Department of Obstetric and Gynecology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA

Benjamin Bonavida Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California, USACorrespondence[email protected]

show all

The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date